CloudMD: Canaccord Lowers Target After Leading $55 Million Bought Deal

On March 9th, CloudMD Software & Services (TSXV: DOC)  announced that their C$55 million bought deal financing closed, with underwriters taking an additional 1.9 million shares equal to C$5.1 million.

CloudMD currently has five analysts covering the company with a weighted 12-month price target of C$3.82. This is down from last month, which was C$3.91. One analyst has a strong buy rating, while the other four have buy ratings on the name.

The street high comes from Laurentian Bank with a C$4.25 price target, and the lowest target comes from Canaccord Genuity with a C$3.50 price target. Laurentian Bank raised their price target from C$4 to C$4.25 while Canaccord downgraded the name from C$3.75 to C$3.50 after they both were a part of the underwriting, with Canaccord Genuity actually leading the underwriting.

Nord Precious Metals — sponsored Sponsored · Nord Precious Metals

Doug Taylor, Canaccord’s analyst, reiterated his speculative buy rating and headlines, “Updating model to reflect reloaded balance sheet and timing of M&A closing.” The main reason for the downgrade was due to the dilution via the financing, while they did very slightly change their full-year 2021 and 2022 revenue estimate.

Taylor believes that after the financing, the company now has on a pro-forma basis C$60 million in cash and “is well-capitalized to pursue additional M&A targets.” The company also announced that they signed a definitive agreement with IDYA4. The company did U$4.4 million in revenue with a 31% EBITDA margin in 2020. The deal is expected to close by the end of March, while Canaccord has moved back the closing date of VisionPros to late in the second quarter.

Taylor touches on the March 2nd partnership with Medavie Blue Cross. He writes, “the announcement highlights CloudMD’s increased focus on digital corporate and insurer offerings in addition to primary health services. We understand that, in recent months, CloudMD has seen success in cross-selling its broader footprint of enterprise-focused solutions to drive organic growth post-acquisition.”

Below you can see Canaccord’s slight estimate changes for the years 2021 and 2022.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

First Majestic Hits 4.24 g/t Gold Over 48.8 Metres at Saval as Jerritt Canyon Restart Advances

First Majestic Lifts Q3 Revenue 38% to US$394.1 Million on Higher Silver Prices

Related News

Medmen: Canaccord Raises Price Target, Rating After Q4 Performance

On September 23, Medmen Enterprises (CSE: MMEN) reported their fiscal fourth-quarter financial results. The company...

Saturday, September 25, 2021, 01:05:00 PM

Canaccord Reiterates Speculative Buy Rating, $3.70 Price Target For Battle North Gold

On Thursday, Battle North Gold (TSXV: BNAU) reported additional high-grade assay results from their confirmatory...

Sunday, September 27, 2020, 01:35:00 PM

Valens Company: Analysts Downgrade Company Following Reduced Guidance

The Valens Company (TSX: VLNS) experienced a pretty wild second half of January, and analysts...

Monday, February 1, 2021, 02:39:00 PM

Suncor: BMO Reiterates Rating, Lowers Price Target To $28

Friday morning, BMO Capital Markets put out a note on Suncor Energy (TSX: SU), upgrading...

Saturday, October 3, 2020, 01:20:00 PM

WeCommerce: Canaccord Lowers Price Target Following Marketing Meetings

Over the last few weeks, Canaccord hosted a number of marketing meetings for WeCommerce (TSXV:...

Wednesday, February 2, 2022, 04:04:00 PM